Llewellyn Simon, MD
Internal Medicine · Lake Providence, LANPI 1063494128
Payments from drug & device makers
Across 303 payments — averaging $43.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- AstraZeneca$1K
- Amgen$702
- Merck$536
- AbbVie$498
- GSK$429
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$6,65050%
- Travel & lodging$1081%
- Food & beverage$6,34848%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 44 | $7,411 |
| AstraZeneca | 61 | $1,417 |
| Amgen | 20 | $702 |
| Merck | 34 | $536 |
| AbbVie(2 entities) | 31 | $498 |
| GSK | 19 | $429 |
| Abbott | 9 | $416 |
| Lilly USA, LLC | 10 | $344 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $311 |
| Bayer | 15 | $280 |
| Boehringer Ingelheim | 8 | $204 |
| Aimmune Therapeutics, Inc. | 5 | $166 |
| Inspire Medical Systems, Inc. | 1 | $99 |
| Ardelyx, Inc. | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $55 |
| Astellas Pharma US Inc | 3 | $46 |
| Nestle Healthcare Nutrition Inc. | 3 | $38 |
| Pfizer | 2 | $37 |
| Mylan Specialty L.p. | 2 | $28 |
| Vivus LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
| Biogen | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$6,770
- BREZTRI$352
- FARXIGA$352
- Repatha$209
- JARDIANCE$124
- LINZESS$123
- FREESTYLE LIBRE 3$122
- EVENITY$104
- TRELEGY ELLIPTA$104
- ZENPEP$103
How this compares
$13,170 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 462 | $492,058 |
| FarxigaDapagliflozin Propanediol | 507 | $343,441 |
| XareltoRivaroxaban | 286 | $151,701 |
| JardianceEmpagliflozin | 173 | $145,885 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $98,537 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $92,977 |
| ZenpepLipase/Protease/Amylase | 45 | $73,792 |
| EliquisApixaban | 138 | $64,851 |
| LinzessLinaclotide | 68 | $51,382 |
| TrulancePlecanatide | 71 | $48,861 |
| XifaxanRifaximin | 14 | $44,235 |
| TrulicityDulaglutide | 45 | $42,125 |
| EntrestoSacubitril/Valsartan | 54 | $41,906 |
| JanuviaSitagliptin Phosphate | 72 | $34,885 |
| Invega SustennaPaliperidone Palmitate | 11 | $33,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $344 | $534,183507 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $1,417 | $455,295679 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Invokana | $7,411 | $200,132311 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $204 | $181,507255 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $429 | $109,459179 claims |
| MerckJanuvia, Isentress, Verquvo, Lagevrio (Eua), Janumet | $536 | $94,501140 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Xifaxan | $311 | $93,09685 claims |
| AbbVieLinzess, Creon | $498 | $76,44087 claims |
| Aimmune Therapeutics, Inc.Zenpep | $166 | $73,79245 claims |
| PfizerEliquis | $37 | $64,851138 claims |
| BayerKerendia | $280 | $7,12112 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $5,15313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lake Providence
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.